Insights

AI Drug Design Collaborations Iktos has engaged in collaborations with Cube Biotech, Synsight, and Elsevier in developing novel drug design solutions, presenting an opportunity to offer AI-driven drug discovery services to other biotech and pharmaceutical companies.

Venture Capital Partnerships Receiving investments from Merck Ventures and completing a successful financing round with prominent partners indicates financial stability and potential growth, making Iktos an attractive partner for biotech investors seeking innovative AI technologies.

Acquisition of Synsight The acquisition of Synsight demonstrates Iktos' strategic expansion in the AI and biotech space, providing a foothold in high-content cell imaging technologies. This acquisition opens doors for offering integrated AI solutions for drug discovery and development.

New Leadership Dynamics The appointment of Avirup Bose as Chief Business Officer highlights Iktos' focus on business development and growth strategies. Leveraging Bose's expertise, Iktos can explore new market segments and forge partnerships within the biotech and pharmaceutical industry.

Sustainable Innovation Initiatives With a focus on developing sustainable crop protection products and collaborations with Bayer's Crop Science division, Iktos is well-positioned to address growing demands for eco-friendly solutions in agriculture, presenting opportunities for expansion into the agricultural biotech market.

iktos Tech Stack

iktos uses 8 technology products and services including TweenMax, jQuery, Webpack, and more. Explore iktos's tech stack below.

  • TweenMax
    Javascript Frameworks
  • jQuery
    Javascript Libraries
  • Webpack
    Miscellaneous
  • Node.js
    Programming Languages
  • PHP
    Programming Languages
  • C++
    Programming Languages
  • MediaElement.js
    Video Players
  • Contact Form 7
    Web Platform Extensions

Media & News

iktos's Email Address Formats

iktos uses at least 1 format(s):
iktos Email FormatsExamplePercentage
First.Last@iktos.aiJohn.Doe@iktos.ai
48%
First@iktos.aiJohn@iktos.ai
3%
First.MiddleLast@iktos.aiJohn.MichaelDoe@iktos.ai
1%
First.Last@iktos.aiJohn.Doe@iktos.ai
48%

Frequently Asked Questions

Where is iktos's headquarters located?

Minus sign iconPlus sign icon
iktos's main headquarters is located at 65, Rue de Prony Paris, Île-de-France 75017 FR. The company has employees across 3 continents, including EuropeNorth AmericaAsia.

What is iktos's official website and social media links?

Minus sign iconPlus sign icon
iktos's official website is iktos.ai and has social profiles on LinkedIn.

How much revenue does iktos generate?

Minus sign iconPlus sign icon
As of January 2025, iktos's annual revenue reached $15M.

What is iktos's SIC code NAICS code?

Minus sign iconPlus sign icon
iktos's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does iktos have currently?

Minus sign iconPlus sign icon
As of January 2025, iktos has approximately 84 employees across 3 continents, including EuropeNorth AmericaAsia. Key team members include Chief Legal Officer: T. B.Chief Business Officer: A. B.Chief Financial Officer: S. M.. Explore iktos's employee directory with LeadIQ.

What industry does iktos belong to?

Minus sign iconPlus sign icon
iktos operates in the Biotechnology Research industry.

What technology does iktos use?

Minus sign iconPlus sign icon
iktos's tech stack includes TweenMaxjQueryWebpackNode.jsPHPC++MediaElement.jsContact Form 7.

What is iktos's email format?

Minus sign iconPlus sign icon
iktos's email format typically follows the pattern of . Find more iktos email formats with LeadIQ.

How much funding has iktos raised to date?

Minus sign iconPlus sign icon
As of January 2025, iktos has raised $16M in funding. The last funding round occurred on Mar 09, 2023 for $16M.

When was iktos founded?

Minus sign iconPlus sign icon
iktos was founded in 2016.
iktos

iktos

Biotechnology ResearchÎle-de-France, France51-200 Employees

We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization.

Our de novo design algorithm is based on deep generative models with reinforcement learning. It designs novel and easy to make compounds, optimized to meet a given multi-objective blueprint, with unprecedented speed, performance, and diversity.

Please visit our webpage to know more about our products and offerings 
https://iktos.ai/products/

Section iconCompany Overview

Headquarters
65, Rue de Prony Paris, Île-de-France 75017 FR
Website
iktos.ai
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
51-200

Section iconFunding & Financials

  • $16M

    iktos has raised a total of $16M of funding over 4 rounds. Their latest funding round was raised on Mar 09, 2023 in the amount of $16M.

  • $10M$50M

    iktos's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $16M

    iktos has raised a total of $16M of funding over 4 rounds. Their latest funding round was raised on Mar 09, 2023 in the amount of $16M.

  • $10M$50M

    iktos's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.